Latest Regulatory Filings News

Coronado Global Resources Inc. posted a $96.2 million net loss for Q1 2025, reflecting weak metallurgical coal prices and ongoing liquidity challenges. The company is navigating covenant waivers and pursuing refinancing amid market uncertainty.

Catalina Resources has successfully completed its entitlement and shortfall offer, raising over $2.27 million to strengthen its cash position and advance its diverse mineral projects.

NSX Limited has successfully closed a $1.3 million share placement, exceeding its initial $1.1 million target and reinforcing its position as Australia’s second largest exchange.

DMC Mining Limited has extended the closing date for its public share offer to August 2025 due to delays in securing exploration licences for its key Guinea projects. The company plans further regulatory updates to accommodate these changes.

Papyrus Australia has issued a revised Appendix 4C for the March 2025 quarter, correcting the treatment of $527k in R&D expenditure previously reported as cash payments. This adjustment also impacts prior monthly and quarterly cash flow reports dating back to November 2024.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

Neurotech International has reported excellent safety and tolerability for its lead drug NTI164 in 28-day GLP toxicology studies, paving the way for regulatory submissions and longer-term clinical development.

Cazaly Resources has issued a replacement Appendix 5B for the March 2025 quarter to correct an administrative error, reaffirming a solid cash position with over six quarters of funding available.

Anagenics Limited reported a cash outflow of $424K for Q3 2025 but maintains robust liquidity with $1.48 million in available funding, supported by a mix of secured and unsecured loans.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Memphasys Limited has completed a pivotal Phase III trial confirming its Felix™ System as best-in-class for sperm separation, while advancing regulatory and commercial efforts in China and Brazil supported by fresh capital.

HALO Technologies reports solid quarterly revenue growth and nears completion of a $6.75 million capital raise, while progressing its UK wealth management platform launch and preparing to introduce Managed Funds in Australia.